NanoCor Therapeutics

NanoCor's Team NanoCor’s team is highly experienced in virology (AAV in particular), in the cardiovascular field and in the development of gene therapy based therapeutics. Dr. Richard Jude Samulski, the developer of the BNP™ technology, has almost 30 years of experience in rAAV and is the Director of the Gene Therapy Center at the University of North Carolina – Chapel Hill. Dr. Evangelia Kranias, the developer of the I-1 technology, is well known for her work in phospholambam and the biology of heart failure, and is the Distinguished Professor and Director of Cardiovascular Biology at the University of Cincinnati. Dr. Roger Hajjar is a leader in gene therapy techniques and model testing for cardiovascular diseases. Management Team Daniel C. Sigg, MD, PhD Chief Executive Officer Leslie Miller, MD Chief Medical Officer Board of Directors Sheila A. Mikhail, J.D., M.B.A. Founder Jude Samulski, Ph.D. Scientific Founder, Collaborator Gerald L. Klein, M.D. Board Member Founders Sheila A. Mikhail, J.D., M.B.A. Founder Gabor M. Rubanyi, M.D., Ph.D. Founder Scientific Collaborators Jude Samulski, Ph.D. Scientific Founder, Collaborator Evangelia Kranias, Ph.D. Scientific Founder, Collaborator Roger Hajjar, MD, Ph.D. Scientific Founder, Collaborator Strategic Partners UNC Chapel Hill Massachusetts General Hospital/Harvard University of Cincinnati Mount Sinai Medical Center Medtronic
	NanoCor's Team
		Management Team Board of Directors Founders Collaborators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	Contact Us
		870 Martin Luther King Jr. Blvd. Chapel Hill, NC 27514 +1-919-636-9506 blake@nanocorthx.com . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

NanoCor Therapeutics, Inc. is engaged in the development of novel therapeutics for the treatment of various cardiovascular diseases at the molecular level. NanoCor’s lead therapeutic is Carfostin™, an intracellular protein therapeutic for the treatment of Chronic Heart Failure (CHF). Carfostin™ is comprised of the delivery of a therapeutic gene, protein Phosphatase-1 Inhibitor-1 (I-1) with the use of Biological NanoParticles (BNPs™) and the Self-Complementary Vector Technology. This novel approach, which represents an important adjunct to existing therapies, will provide a minimal-invasive treatment for these patients and advance the current standard of care.